RWD vs. RWE – How Real-World Data Is Transforming Clinical Research

The clinical research and medical data analytics market is undergoing a technological transformation. Although traditional randomized controlled trials (RCTs) remain the gold standard for evaluating the efficacy of new medicines, the industry is increasingly focusing on Real-World Data (RWD) and Real-World Evidence (RWE).

If you are planning a career in a Contract Research Organization (CRO), biostatistics, or medical data analytics, understanding the differences between RCTs and RWE, as well as knowing the sources of RWD, can be a significant advantage during a job interview.

RWD vs. RWE – What Is the Difference?

These terms are often used together in the industry, but they refer to two distinct stages of working with information:

• Real-World Data (RWD) refers to raw data collected during routine medical practice, outside strictly controlled experimental procedures.
• Real-World Evidence (RWE) refers to scientific and clinical evidence generated through advanced statistical and methodological analysis of RWD.

Put simply, RWD is the raw material (e.g., a record from an electronic health record), while RWE is the finished product (e.g., a report demonstrating that a particular medicine reduces the risk of hospitalization among patients aged 65 and older under real-world conditions).

Why Is Digitalization Driving RWD, and Why Is RWE the Future of the Industry?

The relationship is straightforward: the more advanced healthcare digitalization becomes, the greater the quality, availability, and volume of RWD, strengthening the role of RWE across the healthcare sector.

For decades, medical data was locked away in paper records. Today, the ongoing digitalization of healthcare — from widespread electronic health records (EHRs) and electronic prescriptions to clinical registries, payer databases, telemedicine platforms, Patient Support Programs (PSPs), and wearable devices — is generating an exponential increase in the amount of data collected during routine medical practice.

Why Is This Trend Irreversible?

1. Personalized and targeted medicine: In the era of gene therapies and precision oncology, recruiting large patient populations for traditional RCTs can sometimes be impossible. Regulatory authorities such as the EMA and FDA are increasingly considering RWE analyses, including synthetic control arms, as supporting evidence in drug approval processes.
2. Pressure from payers and HTA agencies: Healthcare payers are no longer interested solely in a medicine's demonstrated efficacy under ideal conditions. They expect evidence of how a treatment performs in real-world, diverse patient populations (effectiveness) and whether it generates measurable savings for healthcare systems (Value-Based Healthcare).
3. Artificial intelligence and machine learning: Modern predictive models and AI algorithms in healthcare require enormous training datasets. Analyzing unstructured EHR data using Natural Language Processing (NLP) creates new opportunities for safety assessment and identifying potential new therapeutic indications.

RCT vs. RWE – How Does RWE Complement Traditional Clinical Trials?

Traditional RCTs use strict patient inclusion and exclusion criteria. This helps ensure patient safety and reliable results, but it can also lead to highly selected study populations. In real-world settings, patients take other medications, have multiple comorbidities, and follow different lifestyles.

Where Does Real-World Data Come From?

When working in a CRO team or a Research and Development (R&D) Center, you may encounter data from a wide range of digital sources:

1. Electronic Medical Records / Electronic Health Records (EMR/EHR): Patient medical histories from primary care clinics, specialist outpatient clinics, and hospitals.
2. Medical Registries and Patient Databases: Cancer registries, cardiovascular registries, and rare disease registries.
3. Insurance and Payer Databases (Claims Data): Information on dispensed prescriptions, healthcare services, and hospitalizations, such as data from Poland's National Health Fund (NFZ).
4. Patient Support Programs (PSPs): Data from mobile applications, short surveys assessing treatment adherence, and Patient-Reported Outcomes (PROs).
5. Wearable Devices: Continuous monitoring of vital signs, physical activity, and glucose levels.

What Will Your Role Be in RWE Projects at a CRO?

Transforming large volumes of digital information into reliable scientific evidence requires an interdisciplinary team. Depending on your professional background, your responsibilities may include:

• For Data Analysts and Statisticians: Data cleaning and structuring (NLP/AI), handling missing data, adjusting for differences between patient populations using methods such as propensity score matching, and developing predictive models.
• For CRAs, Clinical Monitors, and Coordinators: Ensuring that data collection processes comply with GDPR regulations and GCP standards, as well as verifying data quality and integrity at research sites.
• For Study Designers and Researchers (Clinical Data Science): Developing protocols for observational studies, Non-Interventional Studies (NIS), and passive patient registries.

Summary

RWE does not replace RCTs. Instead, it complements them and helps provide evidence throughout the medicinal product lifecycle. The ability to work with data from the digital healthcare ecosystem is becoming one of the most sought-after skills in the clinical research industry.

FAQ – Frequently Asked Questions

1. What Is Real-World Evidence (RWE) in Clinical Research?

Real-World Evidence (RWE) refers to scientific evidence obtained by analyzing data collected during routine medical practice. It can provide information about the effectiveness and safety of treatments under everyday clinical conditions.

2. What Is the Difference Between Real-World Data (RWD) and Real-World Evidence (RWE)?

RWD refers to data about patients' health and healthcare delivery, collected from sources such as medical records, registries, and payer databases. RWE is the evidence generated through appropriately designed analyses of these data.

3. How Do RCTs Differ from Studies Using RWE?

RCTs rely on randomization and controlled conditions, allowing researchers to reliably assess the effects of interventions. Studies using RWE provide information about how treatments are used in routine clinical practice, including among more diverse patient populations. Both approaches can complement each other.

4. What Are the Main Sources of Real-World Data?

RWD sources include electronic medical records and electronic health records (EMR/EHR), patient registries, insurance and payer databases, Patient Support Programs, Patient-Reported Outcomes (PROs), and data from health-monitoring devices.

5. How Is RWE Used in the CRO Industry?

CROs use RWE to conduct observational studies, analyze treatment safety and effectiveness, evaluate patient outcomes, and generate evidence supporting clinical, regulatory, and reimbursement decisions.